Panel divides over wider fentanyl penalties; Senate Judiciary rejects expanded felony measure

Senate Bill 44, a proposal to increase penalties for fentanyl possession, distribution and manufacture, produced sharply divided testimony and emotional appeals from families who have lost children to counterfeit pills. After an extended hearing that included law enforcement, public‑health experts, addiction specialists and numerous family members, the Senate Judiciary Committee voted 3‑4 to reject the measure in committee.

Sponsor Sen. Tim Peltonbee framed the bill as a tool to target drug dealers and cartel activity, reduce street availability of fentanyl and give prosecutors a stronger statutory basis to pursue large‑scale distributors. “This bill takes fentanyl and moves the drug to a class‑1 drug felony if anybody is manufacturing, dispensing, selling or possessing with intent to do the same,” Peltonbee told the committee, and described multiple local law‑enforcement requests to strengthen penalties.

Many law‑enforcement witnesses — from county sheriffs and municipal police chiefs to regional narcotics investigators — urged the committee to move the bill forward. They described lethal potency in the illicit supply, cited local overdose statistics and said tougher penalties would help remove repeat distributors from the street and produce cooperation to reach higher‑level traffickers. Weld County and El Paso County officials told the committee that small‑quantity arrests often uncovered larger supplies at residences, and that a felony framework would provide a stronger enforcement tool.

Family members who lost children to counterfeit pills offered emotional testimony urging stronger penalties. Several described dealers with prior arrests who continued selling; supporters said felony accountability for sellers would have kept dealers off the street when they first appeared in police records.

Opponents — including public‑health researchers, addiction medicine specialists, harm‑reduction providers and civil‑liberties groups — argued that increasing criminal penalties has not reduced overdose deaths and may worsen the crisis. Research presented to the committee included an independent study of Colorado’s 2022 fentanyl sentencing changes (House Bill 1326), which found no population‑level decline in overdose deaths and, in some analyses, adverse outcomes among Black Coloradans. Witnesses warned that stiffer penalties could deter people from calling 911 during overdoses, deepen racial disparities and expand barriers to housing and employment for people with substance use disorders.

Treatment providers and recovery‑housing representatives told the committee that incarceration alone is not a pathway to recovery, noting high post‑release overdose risk when treatment is not continuous. Public defenders and criminal‑justice reform advocates said the bill’s broad strict‑liability language could criminalize unaware users and low‑level purchasers; they urged targeted, intelligence‑led enforcement against traffickers and increased investment in treatment and harm reduction.

Committee members debated the merits of several approaches: stricter penalties for large‑scale and repeat distributors, broader access to treatment and harm‑reduction services, and whether the existing weight‑based thresholds in state law (adopted in 2019 and later amended in 2022) adequately match current threats. The sponsor offered an amendment to preserve prosecutorial discretion for a first qualifying offense while escalating penalties for repeat distribution within two years, but the committee ultimately rejected the bill.

Vote: Senate Judiciary voted 3 in favor, 4 opposed. Sponsors indicated they may seek other ways to pursue enforcement against major dealers while stakeholders called for expanded treatment, housing and harm‑reduction investments as alternatives to broader felony exposure.